$CELC
Celcuity Inc

2023 Q3 Form 10-Q Financial Statement

#000149315223027869 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.410M $1.309M $1.233M
YoY Change 37.96% 6.19% 115.06%
% of Gross Profit
Research & Development $17.49M $13.75M $8.368M
YoY Change 81.76% 64.28% -35.98%
% of Gross Profit
Depreciation & Amortization $30.00K $37.33K $52.45K
YoY Change -43.97% -28.83% -31.53%
% of Gross Profit
Operating Expenses $18.90M $15.06M $9.601M
YoY Change 77.55% 56.82% -29.63%
Operating Profit -$18.90M -$15.06M -$9.601M
YoY Change 77.55% 56.82% -29.63%
Interest Expense $1.372M $1.315M $455.4K
YoY Change 155.2% 188.73% 16.43%
% of Operating Profit
Other Income/Expense, Net $493.5K $467.8K -$359.8K
YoY Change -297.27% -230.02% -7.6%
Pretax Income -$18.40M -$14.59M -$9.961M
YoY Change 68.95% 46.45% -29.02%
Income Tax
% Of Pretax Income
Net Earnings -$18.40M -$14.59M -$9.961M
YoY Change 68.95% 46.45% -29.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.83 -$0.66 -$0.67
Diluted Earnings Per Share -$0.83 -$0.66 -$667.1K
COMMON SHARES
Basic Shares Outstanding 22.09M shares 21.96M shares 14.93M shares
Diluted Shares Outstanding 22.12M shares 21.96M shares 14.93M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $133.9M $146.2M $66.91M
YoY Change 132.94% 118.57% 60.69%
Cash & Equivalents $25.76M $32.24M $66.91M
Short-Term Investments $108.2M $114.0M
Other Short-Term Assets $7.800M $6.562M $4.957M
YoY Change 12.24% 32.39% 1072.18%
Inventory
Prepaid Expenses $7.771M $6.461M $4.602M
Receivables
Other Receivables $95.30K
Total Short-Term Assets $141.7M $152.8M $71.96M
YoY Change 119.05% 112.34% 70.32%
LONG-TERM ASSETS
Property, Plant & Equipment $223.4K $210.9K $238.6K
YoY Change -26.03% -11.64% -42.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $672.7K $710.9K $387.4K
YoY Change 12.59% 83.51% -30.56%
TOTAL ASSETS
Total Short-Term Assets $141.7M $152.8M $71.96M
Total Long-Term Assets $672.7K $710.9K $387.4K
Total Assets $142.4M $153.5M $72.35M
YoY Change 118.07% 112.19% 69.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.635M $3.019M $2.305M
YoY Change 77.86% 31.01% 256.09%
Accrued Expenses $6.887M $3.871M $1.683M
YoY Change 110.08% 129.97% 130.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $0.00 $5.380K
YoY Change -100.0% -100.0% -7.72%
Total Short-Term Liabilities $12.71M $7.082M $4.150M
YoY Change 91.27% 70.64% 170.12%
LONG-TERM LIABILITIES
Long-Term Debt $36.50M $35.99M $15.01M
YoY Change 143.12% 139.72% 5.43%
Other Long-Term Liabilities $300.0K $317.1K $0.00
YoY Change 178.22%
Total Long-Term Liabilities $36.80M $36.30M $15.01M
YoY Change 143.37% 141.84% 5.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.71M $7.082M $4.150M
Total Long-Term Liabilities $36.80M $36.30M $15.01M
Total Liabilities $49.49M $43.38M $19.16M
YoY Change 127.36% 126.42% 21.47%
SHAREHOLDERS EQUITY
Retained Earnings -$141.2M -$122.8M -$73.82M
YoY Change 66.71% 66.38%
Common Stock $22.37K $22.08K $14.94K
YoY Change 49.7% 47.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $92.90M $110.1M $53.19M
YoY Change
Total Liabilities & Shareholders Equity $142.4M $153.5M $72.35M
YoY Change 118.07% 112.19% 69.01%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$18.40M -$14.59M -$9.961M
YoY Change 68.95% 46.45% -29.02%
Depreciation, Depletion And Amortization $30.00K $37.33K $52.45K
YoY Change -43.97% -28.83% -31.53%
Cash From Operating Activities -$12.75M -$9.662M -$11.29M
YoY Change 37.0% -14.41% 48.17%
INVESTING ACTIVITIES
Capital Expenditures $50.00K $4.850K -$22.98K
YoY Change -513.22% -121.11% -17.63%
Acquisitions
YoY Change
Other Investing Activities $6.300M $8.095M $0.00
YoY Change -100.0%
Cash From Investing Activities $6.250M $8.090M -$22.98K
YoY Change -51752.89% -35304.48% -16.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 171.5K -72.51K
YoY Change -109.24% -336.59% -100.51%
NET CHANGE
Cash From Operating Activities -12.75M -9.662M -11.29M
Cash From Investing Activities 6.250M 8.090M -22.98K
Cash From Financing Activities 10.00K 171.5K -72.51K
Net Change In Cash -6.490M -1.401M -11.38M
YoY Change -31.16% -87.7% -269.9%
FREE CASH FLOW
Cash From Operating Activities -$12.75M -$9.662M -$11.29M
Capital Expenditures $50.00K $4.850K -$22.98K
Free Cash Flow -$12.80M -$9.667M -$11.27M
YoY Change 37.71% -14.19% 48.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001603454
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 CELC Payroll Tax Receivable
PayrollTaxReceivable
usd
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
CELC Offering And Registration Statement Costs Included In Accrued Expenses
OfferingAndRegistrationStatementCostsIncludedInAccruedExpenses
usd
CELC Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
usd
CY2023Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38207
dei Entity Registrant Name
EntityRegistrantName
CELCUITY INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2863566
dei Entity Address Address Line1
EntityAddressAddressLine1
16305 36th Avenue North; Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55446
dei City Area Code
CityAreaCode
(763)
dei Local Phone Number
LocalPhoneNumber
392-0767
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CELC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22090143 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32238702 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24571557 usd
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
114005385 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
144015954 usd
CY2023Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 usd
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 usd
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
79088 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
33195 usd
CY2022Q4 CELC Payroll Tax Receivable
PayrollTaxReceivable
203665 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6461156 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6344157 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
152806340 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
175190537 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
210858 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260294 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
499993 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
246266 usd
CY2023Q2 us-gaap Assets
Assets
153517191 usd
CY2022Q4 us-gaap Assets
Assets
175697097 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3019282 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2627076 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2449 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
191333 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
191749 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3871135 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4060280 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7081750 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6881554 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
317120 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61002 usd
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
35985980 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
34983074 usd
CY2023Q2 us-gaap Liabilities
Liabilities
43384850 usd
CY2022Q4 us-gaap Liabilities
Liabilities
41925630 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1085873 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1085873 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1120873 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1120873 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
1086 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1121 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22081893 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22081893 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21667250 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21667250 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
22082 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
21667 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
232932164 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230045566 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122822991 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96296887 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110132341 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153517191 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175697097 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13746082 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8367687 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25024575 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15064000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1309403 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1233040 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2578447 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2044332 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
15055485 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9600727 usd
us-gaap Operating Expenses
OperatingExpenses
27603022 usd
us-gaap Operating Expenses
OperatingExpenses
17108332 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15055485 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9600727 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-27603022 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17108332 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
1314996 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
455445 usd
us-gaap Interest Expense
InterestExpense
2557008 usd
us-gaap Interest Expense
InterestExpense
890446 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1276982 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
102638 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
113640 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1782794 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
95646 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3633926 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
103805 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
467798 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-359799 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1076918 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-786641 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14587687 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9960526 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26526104 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17894973 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-14587687 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9960526 usd
us-gaap Net Income Loss
NetIncomeLoss
-26526104 usd
us-gaap Net Income Loss
NetIncomeLoss
-17894973 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21957140 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21957140 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14930538 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14930538 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21819772 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21819772 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14923900 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14923900 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21957140 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14930538 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21819772 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14923900 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1273282 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
127922 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
7486 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11938417 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
123226768 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-14587687 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110132341 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
756271 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7414 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7934447 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61539715 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1519459 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80541 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9542 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9960526 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
53188731 usd
us-gaap Net Income Loss
NetIncomeLoss
-26526104 usd
us-gaap Net Income Loss
NetIncomeLoss
-17894973 usd
us-gaap Depreciation
Depreciation
81269 usd
us-gaap Depreciation
Depreciation
108436 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2550264 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2275730 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
116218 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
179539 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
886688 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
205998 usd
CELC Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
1975 usd
CELC Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-1686 usd
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-41188 usd
CELC Increase Decrease In Payroll Tax Receivable
IncreaseDecreaseInPayrollTaxReceivable
-203665 usd
CELC Increase Decrease In Payroll Tax Receivable
IncreaseDecreaseInPayrollTaxReceivable
-203464 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
116999 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3879197 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
421091 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
705145 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-189145 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
875412 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22529890 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17222132 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
143873027 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
113903646 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11841 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34621 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29957540 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34621 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
241562 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16956 usd
CELC Proceeds From Employee Stock Purchases
ProceedsFromEmployeeStockPurchases
102638 usd
CELC Proceeds From Employee Stock Purchases
ProceedsFromEmployeeStockPurchases
80541 usd
CELC Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
99540 usd
CELC Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
213381 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2716 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2449 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2920 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
239495 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-118804 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7667145 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17375557 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24571557 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84286381 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32238702 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66910824 usd
us-gaap Interest Paid Net
InterestPaidNet
1554103 usd
us-gaap Interest Paid Net
InterestPaidNet
504909 usd
CELC Offering And Registration Statement Costs Included In Accounts Payable
OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
2143 usd
CELC Offering And Registration Statement Costs Included In Accounts Payable
OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
100422 usd
CELC Offering And Registration Statement Costs Included In Accrued Expenses
OfferingAndRegistrationStatementCostsIncludedInAccruedExpenses
5000 usd
CELC Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
19993 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zNkcLXAp0HMc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Accounting Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
355578 usd
CY2023Q2 us-gaap Contractual Obligation
ContractualObligation
2000000.0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zUEMg6euIQyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
114005385 usd
CY2023Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
30500 usd
CY2023Q2 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
114035885 usd
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
144015954 usd
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
71156 usd
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
144087110 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21667250 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1120873 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22081893 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1085873 shares
us-gaap Dividends
Dividends
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0341 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0414 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0168 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.031 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.780 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.798 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.762 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.783 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedRemainderOfFiscalYear
1878430 usd
CY2023Q2 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognized Next Twelve Months
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths
2588676 usd
CY2023Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Two Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear
1602483 usd
CY2023Q2 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognizedwithin Three Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears
614044 usd
CY2023Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Four Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears
94968 usd
CY2023Q2 CELC Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost To Be Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized
6778601 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1276982 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1519459 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2550264 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2275730 usd
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000000 usd
CY2023Q2 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
1641763 usd
CY2022Q4 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
755075 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
598107 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
707001 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
57676 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
65000 usd
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
35985980 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
34983074 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
13740661 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18320882 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4580220 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
36641763 usd

Files In Submission

Name View Source Status
0001493152-23-027869-index-headers.html Edgar Link pending
0001493152-23-027869-index.html Edgar Link pending
0001493152-23-027869.txt Edgar Link pending
0001493152-23-027869-xbrl.zip Edgar Link pending
celc-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
celc-20230630_cal.xml Edgar Link unprocessable
celc-20230630_def.xml Edgar Link unprocessable
celc-20230630_lab.xml Edgar Link unprocessable
celc-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending